Evolution of monoclonal antibodies in multiple myeloma
Mené sur 73 patients atteints d'un myélome multiple récidivant ou réfractaire, cet essai de phase I évalue la dose maximale tolérée, l'activité clinique préliminaire et la toxicité d'un composé appelé GSK2857916, un conjugué anticorps-médicament anti-BCMA
Immunotherapy represents the most innovative approach developed in the past decades for the treatment of multiple myeloma. Monoclonal antibodies, in particular, differ substantially from all other agents used in this disease, because of their capacity to stimulate immune-competent cells to kill neoplastic plasma cells. Two of these molecules, elotuzumab and daratumumab, are licensed for selected populations of patients with multiple myeloma.
The Lancet Oncology , commentaire, 2017